Revolutionizing Cancer Therapeutics: TransCode Therapeutics, Inc. Secures $8 Million in Funding

TransCode Therapeutics, Inc. is thrilled to announce the successful completion of an $8 million funding round, a significant leap forward in their mission to pave the way for a cancer-free future for all patients. With a steadfast belief that cancer can be conquered through intelligently designed and efficiently delivered targeted therapeutics, TransCode is committed to revolutionizing the approach to cancer treatment. The funding will enhance the development of TTX-MC138, their lead therapeutic candidate that specifically targets microRNA-10b, widely recognized as the master regulator of metastatic cell viability across various cancers, including breast, pancreatic, and colon cancers. In addition to TTX-MC138, this new capital will also support their innovative preclinical programs, including TTX-siPDL1, TTX-siLIN28B, and groundbreaking cancer agnostic initiatives such as TTX-RIGA, TTX-CRISPR, and TTX-mRNA. TransCode's revolutionary proprietary delivery platform, TTX, aims to overcome the historic challenges associated with delivering targeted therapeutics effectively, addressing the critical unmet needs of a disease that affects millions worldwide. With their world-class team and expertise, TransCode is poised to drastically change the landscape of cancer treatment through their diverse pipeline of drug candidates. This funding not only accelerates their research and development efforts but also reinforces their commitment to developing transformative therapies that could profoundly impact long-term survival rates for cancer patients globally. As they embark on this promising journey, TransCode remains dedicated to delivering innovative solutions that ultimately strive towards a world free from cancer.